Lunaphore and Visiopharm: Partnership to unify spatial staining and imaging with AI analysis technologies in end-to-end solution for researchers studying cancer and other diseases. LAUSANNE, Switzerland and HØRSHOLM, Denmark – May 4, 2022...

Augsburg University Hospital, one of Germany’s leading hospitals, has selected Visiopharm, a world-leading developer of precision AI image analysis software, to realise its ambition of becoming a digital pathology powerhouse. The...

March 21, 2022: Today, Visiopharm launches Qualitopix™ for AI-driven standardization of tissue staining at USCAP 2022 is introducing its novel and unique Qualitopix™ solution to delegates at the United States and Canadian Academy of...

Proscia and Visiopharm: Partnership to improve clinical decision making for breast and colon cancer care HOERSHOLM, Denmark & PHILADELPHIA – March 22, 2022 – Proscia®, a leader in digital and computational pathology solutions, and...

Visiopharm has announced preregistration for their USCAP 2022 seminar. AI-driven stain quality standardization of IHC Featuring Marilyn M. Bui, MD, Ph.D., Moffitt Cancer Center and Martin Kristensson, Visiopharm Wednesday, March 23rd,...

Visiopharm, a world leader in AI-driven precision pathology software, today announced that its existing portfolio of diagnostic apps have all been certified under the new In Vitro Diagnostic Regulation (IVDR). The major difference between...